Abstract
Oligonucleotides, whether synthesized or generated by selective enrichment strategies, are long-established research tools. A decade ago, new production and in vivo delivery techniques saw them emerge as a novel class of molecular therapeutics, and this advancement has evolved rapidly, driven by noteworthy discoveries that enlightened our understanding of gene function in disease pathogenesis. RNA aptamers and short interfering RNA (siRNA) are at the forefront of clinical development, but other technologies offer additional promise. Here, we focus on three distinct oligonucleotide therapies, which nevertheless have potential to treat dyslipoproteinemias and atherosclerosis: RNA interference, exon skipping, and oligonucleotide-directed gene editing. The first two are now recognized examples of antisense oligonucleotide technology for manipulating gene expression, while targeted gene editing is an unexpected development, uniquely suited for the safe introduction of small, permanent changes into a cell’s genome.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008;29:11-26.
Chester A, Scott J, Anant S, Navaratnam N. RNA editing: cytidine to uridine conversion in apolipoprotein B mRNA. Biochim Biophys Acta. 2000;1494:1-13.
Olofsson SO, Asp L, Boren J. The assembly and secretion of apolipoprotein B-containing lipoproteins. Curr Opin Lipidol. 1999;10:341-346.
Owen JS, Mulcahy JV. ATP-binding cassette A1 protein and HDL homeostasis. Atheroscler Suppl. 2002;3:13-22.
Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116:3090-3100.
Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2004;24:421-428.
Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem. 2002;277:17377-17380.
Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161-169.
Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res. 2003;44:878-883.
Burnett JR, Shan J, Miskie BA, et al. A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. J Biol Chem. 2003;278:13442-12352.
Tarugi P, Lonardo A, Ballarini G, et al. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J Hepatol. 2000;33:361-370.
Zamel R, Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis. 2008;3:1.
Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest. 1994;93:223-229.
Dastani Z, Dangoisse C, Boucher B, et al. A novel nonsense apolipoprotein A-I mutation (apoA-I(E136X)) causes low HDL cholesterol in French Canadians. Atherosclerosis. 2006;185:127-136.
Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892-900.
Calabresi L, Sirtori CR, Paoletti R, Franceschini G. Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. Curr Atheroscler Rep. 2006;8:163-167.
Favari E, Gomaraschi M, Zanotti I, et al. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding cassette A1-mediated cell cholesterol efflux. J Biol Chem. 2007;282:5125-5132.
Disterer P, Osman E, Owen JS. Gene therapy for apolipoprotein A-I and HDL-the ultimate treatment for atherosclerosis? In: Abraham D, Handler C, Dashwood M, Coghlan G, eds. Vascular Complications in Human Disease. Mechanisms and Consequences. London: Springer; 2007.
Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537.
Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J Lipid Res. 1999;40:1933-1949.
Fazekas F, Enzinger C, Ropele S, Schmidt H, Schmidt R, Strasser-Fuchs S. The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis. J Neurol Sci. 2006;245:35-39.
Folsom AR, Peacock JM, Boerwinkle E. Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis. 2009;202:211-215.
Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis. 2009;2003:1-7.
Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161-165.
Wilson C, Keefe AD. Building oligonucleotide therapeutics using non-natural chemistries. Curr Opin Chem Biol. 2006;10:607-614.
Keefe AD, Schaub RG. Aptamers as candidate therapeutics for cardiovascular indications. Curr Opin Pharmacol. 2008;8:147-152.
Bhindi R, Fahmy RG, Lowe HC, et al. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol. 2007;171:1079-1088.
Novina CD, Sharp PA. The RNAi revolution. Nature. 2004;430:161-164.
Aartsma-Rus A, van Ommen GJ. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA. 2007;13:1609-1624.
Parekh-Olmedo H, Kmiec EB. Progress and prospects: targeted gene alteration (TGA). Gene Ther. 2007;14:1675-1680.
Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432:173-178.
Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111-114.
Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008;105:11915-11920.
Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002;3:285-298.
Krämer A. The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu Rev Biochem. 1996;65:367-409.
Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science. 2004;306:1796-1799.
van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007;357:2677-2686.
Khoo B, Roca X, Chew SL, Krainer AR. Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB. BMC Mol Biol. 2007;8:3.
Dekker M, Brouwers C, te Riele H. Targeted gene modification in mismatch-repair-deficient embryonic stem cells by single-stranded DNA oligonucleotides. Nucleic Acids Res. 2003;31:e27.
Yoon K, Cole-Strauss A, Kmiec EB. Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA-DNA oligonucleotide. Proc Natl Acad Sci U S A. 1996;93:2071-2076.
Cole-Strauss A, Yoon K, Xiang Y, et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science. 1996;273:1386-1389.
Tagalakis AD, Graham IR, Riddell DR, Dickson JG, Owen JS. Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeraplasty. J Biol Chem. 2001;276:13226-13230.
Tagalakis AD, Dickson G, Owen JS, Simons PJ. Gene correction of human apolipoprotein (apo) E4 to apoE3 in vitro using synthetic RNA/DNA oligonucleotides (chimeraplasts). J Mol Neurosci. 2005;25:95-104.
Manzano A, Mohri Z, Sperber G, et al. Failure to generate atheroprotective apolipoprotein AI phenotypes using synthetic RNA/DNA oligonucleotides (chimeraplasts). J Gene Med. 2003;5:795-802.
van der Steege G, Schuilenga-Hut PH, Buys CH, Scheffer H, Pas HH, Jonkman MF. Persistent failures in gene repair. Nat Biotechnol. 2001;19:305-306.
Taubes G. The strange case of chimeraplasty. Science. 2002;298:2116-2120.
Ferrara L, Kmiec EB. Targeted gene repair activates Chk1 and Chk2 and stalls replication in corrected cells. DNA Repair (Amst). 2006;5:422-431.
Olsen PA, Randol M, Krauss S. Implications of cell cycle progression on functional sequence correction by short single-stranded DNA oligonucleotides. Gene Ther. 2005;12:546-551.
Disterer P, Simons JP, Owen JS. Validation of oligonucleotide-mediated gene editing. Gene Ther. 2009;16:824-826.
Papaioannou I, Disterer P, Owen JS. Use of internally nuclease-protected single-strand DNA oligonucleotides and silencing the mismatch repair protein, MSH2, enhance replication of corrected cells following gene editing. J Gene Med. 2009;11:267-274.
Radecke S, Radecke F, Peter I, Schwarz K. Physical incorporation of a single-stranded oligodeoxynucleotide during targeted repair of a human chromosomal locus. J Gene Med. 2006;8:217-228.
Morozov V, Wawrousek EF. Single-strand DNA-mediated targeted mutagenesis of genomic DNA in early mouse embryos is stimulated by Rad51/54 and by Ku70/86 inhibition. Gene Ther. 2007;15:468-472.
Olsen PA, Randøl M, Luna L, Brown T, Krauss S. Genomic sequence correction by single-stranded DNA oligonucleotides: role of DNA synthesis and chemical modifications of the oligonucleotide ends. J Gene Med. 2005;7:1534-1544.
Igoucheva O, Alexeev V, Scharer O, Yoon K. Involvement of ERCC1/XPF and XPG in oligodeoxynucleotide-directed gene modification. Oligonucleotides. 2006;16:94-104.
Pierce EA, Liu Q, Igoucheva O, et al. Oligonucleotide-directed single-base DNA alterations in mouse embryonic stem cells. Gene Ther. 2003;10:24-33.
Aarts M, Dekker M, de Vries S, van der Wal A, te Riele H. Generation of a mouse mutant by oligonucleotide-mediated gene modification in ES cells. Nucleic Acids Res. 2006;34:e147.
Carroll D. Progress and prospects: Zinc-finger nucleases as gene therapy agents. Gene Ther.. 2008;15:1463-1468.
Cathomen T, Joung JK. Zinc-finger nucleases: the next generation. Mol Ther. 2008;16:1200-1207.
Moehle EA, Rock JM, Lee YL, et al. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc Natl Acad Sci U S A. 2007;104:3055-3060.
Acknowledgments
Dr Papaioannou was supported by a British Heart Foundation project grant (PG/06/015/20305).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag London
About this chapter
Cite this chapter
Papaioannou, I., Owen, J.S. (2009). Oligonucleotide Therapeutics to Treat Dyslipoproteinemia and Atherosclerosis. In: Abraham, D., Clive, H., Dashwood, M., Coghlan, G. (eds) Advances in Vascular Medicine. Springer, London. https://doi.org/10.1007/978-1-84882-637-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-84882-637-3_1
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84882-636-6
Online ISBN: 978-1-84882-637-3
eBook Packages: MedicineMedicine (R0)